S&P 500   3,131.77 (+0.11%)
DOW   27,099.98 (+0.07%)
QQQ   216.58 (+0.56%)
AAPL   291.45 (+1.17%)
FB   197.34 (+0.29%)
MSFT   169.76 (+1.01%)
GOOGL   1,394.91 (+0.62%)
AMZN   1,972.56 (+-0.01%)
CGC   19.92 (+1.53%)
NVDA   266.86 (+1.84%)
BABA   209.89 (+2.08%)
MU   52.72 (+1.19%)
GE   11.16 (-1.41%)
TSLA   793.30 (-0.83%)
AMD   47.94 (+0.78%)
T   37.25 (-0.29%)
F   7.32 (+1.24%)
NFLX   373.84 (+3.82%)
PRI   121.91 (+0.40%)
BAC   30.86 (-0.71%)
DIS   125.08 (-2.43%)
GILD   72.04 (+2.77%)
S&P 500   3,131.77 (+0.11%)
DOW   27,099.98 (+0.07%)
QQQ   216.58 (+0.56%)
AAPL   291.45 (+1.17%)
FB   197.34 (+0.29%)
MSFT   169.76 (+1.01%)
GOOGL   1,394.91 (+0.62%)
AMZN   1,972.56 (+-0.01%)
CGC   19.92 (+1.53%)
NVDA   266.86 (+1.84%)
BABA   209.89 (+2.08%)
MU   52.72 (+1.19%)
GE   11.16 (-1.41%)
TSLA   793.30 (-0.83%)
AMD   47.94 (+0.78%)
T   37.25 (-0.29%)
F   7.32 (+1.24%)
NFLX   373.84 (+3.82%)
PRI   121.91 (+0.40%)
BAC   30.86 (-0.71%)
DIS   125.08 (-2.43%)
GILD   72.04 (+2.77%)
S&P 500   3,131.77 (+0.11%)
DOW   27,099.98 (+0.07%)
QQQ   216.58 (+0.56%)
AAPL   291.45 (+1.17%)
FB   197.34 (+0.29%)
MSFT   169.76 (+1.01%)
GOOGL   1,394.91 (+0.62%)
AMZN   1,972.56 (+-0.01%)
CGC   19.92 (+1.53%)
NVDA   266.86 (+1.84%)
BABA   209.89 (+2.08%)
MU   52.72 (+1.19%)
GE   11.16 (-1.41%)
TSLA   793.30 (-0.83%)
AMD   47.94 (+0.78%)
T   37.25 (-0.29%)
F   7.32 (+1.24%)
NFLX   373.84 (+3.82%)
PRI   121.91 (+0.40%)
BAC   30.86 (-0.71%)
DIS   125.08 (-2.43%)
GILD   72.04 (+2.77%)
S&P 500   3,131.77 (+0.11%)
DOW   27,099.98 (+0.07%)
QQQ   216.58 (+0.56%)
AAPL   291.45 (+1.17%)
FB   197.34 (+0.29%)
MSFT   169.76 (+1.01%)
GOOGL   1,394.91 (+0.62%)
AMZN   1,972.56 (+-0.01%)
CGC   19.92 (+1.53%)
NVDA   266.86 (+1.84%)
BABA   209.89 (+2.08%)
MU   52.72 (+1.19%)
GE   11.16 (-1.41%)
TSLA   793.30 (-0.83%)
AMD   47.94 (+0.78%)
T   37.25 (-0.29%)
F   7.32 (+1.24%)
NFLX   373.84 (+3.82%)
PRI   121.91 (+0.40%)
BAC   30.86 (-0.71%)
DIS   125.08 (-2.43%)
GILD   72.04 (+2.77%)
Log in

NYSE:SNY - Sanofi Stock Price, Forecast & News

$49.30
+0.29 (+0.59 %)
(As of 02/26/2020 12:20 PM ET)
Today's Range
$48.81
Now: $49.30
$49.60
50-Day Range
$47.77
MA: $50.22
$51.66
52-Week Range
$40.00
Now: $49.30
$51.84
Volume839,203 shs
Average Volume1.61 million shs
Market Capitalization$123.45 billion
P/E Ratio15.75
Dividend Yield2.33%
Beta0.67
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.60 billion
Cash Flow$5.42 per share
Book Value$26.11 per share

Profitability

Net Income$4.28 billion

Miscellaneous

EmployeesN/A
Outstanding Shares2,504,138,000
Market Cap$123.45 billion
Next Earnings Date4/24/2020 (Estimated)
OptionableOptionable

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.


Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) issued its earnings results on Wednesday, October, 31st. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.98 by $0.09. The company earned $9.39 billion during the quarter, compared to analysts' expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Sanofi.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided EPS guidance of 6.05-6.05 for the period.

What price target have analysts set for SNY?

12 Wall Street analysts have issued 12-month price targets for Sanofi's stock. Their forecasts range from $52.00 to $58.00. On average, they expect Sanofi's share price to reach $55.33 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View Analyst Price Targets for Sanofi.

What is the consensus analysts' recommendation for Sanofi?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s Q4 results were mixed as it beat on earnings and missed on sales. Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. The drug has, in a very short time, become the key top-line driver for Sanofi. The performance of the Vaccines franchise has also improved of late. Sanofi’s R&D pipeline is strong and it delivered several positive data read-outs and achieved regulatory milestones in 2019 with the momentum expected to continue in 2020. Its cost savings and efficiency initiatives are supporting bottom-line growth. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past one year." (2/19/2020)
  • 2. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)

Has Sanofi been receiving favorable news coverage?

News stories about SNY stock have been trending very positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sanofi earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), AT&T (T), Merck & Co., Inc. (MRK), AbbVie (ABBV), Alibaba Group (BABA), Walt Disney (DIS), Exxon Mobil (xom), Bank of America (BAC) and Pfizer (PFE).

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (0.42%), Bank of America Corp DE (0.29%), Hotchkis & Wiley Capital Management LLC (0.14%), Hamlin Capital Management LLC (0.07%), Brandes Investment Partners LP (0.07%) and Artisan Partners Limited Partnership (0.06%). View Institutional Ownership Trends for Sanofi.

Which major investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Point72 Asset Management L.P., Brandes Investment Partners LP, Alliancebernstein L.P., Baird Financial Group Inc., Schonfeld Strategic Advisors LLC, Franklin Resources Inc. and Guardian Capital LP. View Insider Buying and Selling for Sanofi.

Which major investors are buying Sanofi stock?

SNY stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Cambiar Investors LLC, Hotchkis & Wiley Capital Management LLC, Credit Suisse AG, Marshall Wace LLP, Schafer Cullen Capital Management Inc and Natixis Advisors L.P.. View Insider Buying and Selling for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $49.30.

How big of a company is Sanofi?

Sanofi has a market capitalization of $123.45 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. View Additional Information About Sanofi.

What is Sanofi's official website?

The official website for Sanofi is http://www.sanofi.com/.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (NYSE SNY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  463 (Vote Outperform)
Underperform Votes:  561 (Vote Underperform)
Total Votes:  1,024
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel